Inhibrx Biosciences, Inc. 8-K

What Happened

• On May 11, 2026 Inhibrx Biosciences, Inc. (INBX) filed a Form 8‑K to disclose a press release with clinical updates on its drug candidate INBRX‑106 in first‑line head and neck squamous cell carcinoma (HNSCC).
• The press release was furnished as Exhibit 99.1 to the 8‑K, and an updated corporate presentation was posted to the “Investors” tab of Inhibrx’s website and attached as Exhibit 99.2.

Key Details

• Filing date: May 11, 2026 (Form 8‑K, Items 7.01 and 8.01).
• Materials made public: Press release (Exhibit 99.1) and updated investor presentation (Exhibit 99.2).
• Website: Updated presentation posted at www.inhibrx.com (Investors tab).
• Form 8‑K signed by Kelly Deck, Chief Financial Officer of Inhibrx.

Why It Matters

• This disclosure makes the company’s latest clinical information on INBRX‑106 publicly available under Regulation FD, ensuring all investors have equal access to the update.
• Updated corporate presentation can contain additional details or timelines about the INBRX‑106 program and is likely to be used in investor outreach and analyst briefings.
• Investors tracking Inhibrx’s clinical progress or valuation should review the press release and presentation for specifics; the 8‑K itself supplies the official public record of those materials.